BBVA USA Bancshares’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
$6.36M Buy
74,414
+6,320
+9% +$567K 0.3% 86
2020
Q4
$6.43M Sell
68,094
-6,534
-9% -$571K 0.33% 78
2020
Q3
$6.49M Buy
74,628
+715
+1% +$61.9K 0.37% 66
2020
Q2
$6.46M Buy
73,913
+7,704
+12% +$665K 0.39% 66
2020
Q1
$5.46M Buy
66,209
+28,498
+76% +$2.54M 0.39% 65
2019
Q4
$3.57M Buy
37,711
+397
+1% +$35.6K 0.2% 115
2019
Q3
$3.24M Sell
37,314
-1,350
-3% -$121K 0.21% 119
2019
Q2
$3.53M Sell
38,664
-1,960
-5% -$166K 0.21% 115
2019
Q1
$3.5M Buy
40,624
+189
+0.5% +$15.2K 0.22% 109
2018
Q4
$3.11M Sell
40,435
-1,292
-3% -$101K 0.22% 104
2018
Q3
$3.22M Sell
41,727
-39
-0.1% -$2.88K 0.19% 122
2018
Q2
$2.83M Sell
41,766
-2,441
-6% -$168K 0.18% 126
2018
Q1
$3.2M Sell
44,207
-2,155
-5% -$164K 0.21% 111
2017
Q4
$3.49M Sell
46,362
-2,146
-4% -$162K 0.22% 105
2017
Q3
$3.73M Buy
48,508
+549
+1% +$41.5K 0.24% 98
2017
Q2
$3.59M Sell
47,959
-1,139
-2% -$80.7K 0.24% 100
2017
Q1
$3.27M Sell
49,098
-657
-1% -$43.8K 0.22% 109
2016
Q4
$3.25M Sell
49,755
-25,700
-34% -$1.67M 0.23% 107
2016
Q3
$5.34M Buy
75,455
+5,204
+7% +$379K 0.39% 66
2016
Q2
$5.19M Buy
70,251
+1,881
+3% +$130K 0.39% 67
2016
Q1
$4.44M Buy
68,370
+10,778
+19% +$733K 0.33% 74
2015
Q4
$4.44M Sell
57,592
-7,961
-12% -$632K 0.33% 79
2015
Q3
$5.4M Buy
65,553
+5,093
+8% +$453K 0.42% 66
2015
Q2
$5.33M Buy
60,460
+7,322
+14% +$672K 0.3% 93
2015
Q1
$4.7M Buy
53,138
+5,795
+12% +$514K 0.21% 138
2014
Q4
$3.93M Buy
47,343
+8,361
+21% +$693K 0.18% 150
2014
Q3
$3.29M Buy
38,982
+27,071
+227% +$2.19M 0.15% 161
2014
Q2
$966K Buy
11,911
+894
+8% +$70.3K 0.04% 280
2014
Q1
$839K Buy
11,017
+386
+4% +$28.1K 0.04% 292
2013
Q4
$766K Buy
10,631
+3,352
+46% +$233K 0.03% 297
2013
Q3
$500K Buy
7,279
+1,389
+24% +$91.9K 0.02% 327
2013
Q2
$374K Buy
+5,890
New +$383K 0.02% 349

Other funds holding NVS

BBVA USA Bancshares's NVS Position: Q1 2021 in Review

BBVA USA Bancshares increased its Novartis (NVS) stake by 9.3% in Q1 2021, buying an estimated $567K and bringing the position to 74,414 shares worth $6.36M. The position accounts for 0.3% of the portfolio, ranked #86.

BBVA USA Bancshares first reported a position in NVS in Q2 2013 and has held it in 32 quarters since. The position peaked at $6.49M in Q3 2020. 1,136 funds tracked by Wall St. Rank hold NVS as of Q1 2021.

  • BBVA USA Bancshares held 74,414 shares of Novartis worth $6.36M as of Q1 2021.
  • BBVA USA Bancshares bought 6,320 Novartis shares in Q1 2021, an estimated $567K.
  • Novartis made up 0.3% of BBVA USA Bancshares's portfolio in Q1 2021, its #86 holding.
  • BBVA USA Bancshares first reported a position in Novartis in Q2 2013 and has held it in 32 quarters since.
  • BBVA USA Bancshares's Novartis position peaked at $6.49M in Q3 2020.
  • 1,136 funds tracked by Wall St. Rank held Novartis as of Q1 2021.

Based on BBVA USA Bancshares's 13F filing for Q1 2021, filed 23 Apr 2021.